公开(公告)号：DE3012209A1

公开(公告)日：1980-10-09

申请号：DE3012209

申请日：1980-03-28

Applicant: ABBOTT LAB

Inventor： TADANIER JOHN SOLOMAN ,  HALLAS ROBERT ,  MARTIN JERRY ROY

IPC: C07H15/224 ,  C07H15/22 ,  A61K31/71

Abstract: What is described is 2-epi-fortimicin A, 2-epi-fortimicin B or a 2-epi-fortimicin B derivative represented by the formula: wherein R1 is hydrogen or loweralkyl; R2 is hydrogen or hydroxy; R3 is methyl or hydrogen; and R4 is selected from the group consisting of hydrogen, loweralkyl, aminoloweralkyl, diaminoloweralkyl, N-loweralkylaminoalkyl, N,N-diloweralkylaminoloweralkyl, hydroxyloweralkyl, aminohydroxyloweralkyl, N-loweralkylaminohydroxyloweralkyl, N,N-diloweralkylaminohydroxyloweralkyl, acyl of the formula wherein R5 is loweralkyl, aminoacyl, diaminoacyl, hydroxyacyl, N-loweralkylaminoacyl, N,N-diloweralkylaminoacyl, hydroxy-substituted aminoacyl or an amino acid residue other than those defined above and the pharmaceutically acceptable salts thereof useful in the treatment of infections.

公开(公告)号：AU5685280A

公开(公告)日：1980-10-02

申请号：AU5685280

申请日：1980-03-26

Applicant: ABBOTT LAB

Inventor： TADANIER JOHN SOLOMAN ,  HALLAS ROBERT ,  MARTIN JERRY ROY

IPC: C07H15/224 ,  C07H15/22

Abstract: What is described is 2-epi-fortimicin A, 2-epi-fortimicin B or a 2-epi-fortimicin B derivative represented by the formula: wherein R1 is hydrogen or loweralkyl; R2 is hydrogen or hydroxy; R3 is methyl or hydrogen; and R4 is selected from the group consisting of hydrogen, loweralkyl, aminoloweralkyl, diaminoloweralkyl, N-loweralkylaminoalkyl, N,N-diloweralkylaminoloweralkyl, hydroxyloweralkyl, aminohydroxyloweralkyl, N-loweralkylaminohydroxyloweralkyl, N,N-diloweralkylaminohydroxyloweralkyl, acyl of the formula wherein R5 is loweralkyl, aminoacyl, diaminoacyl, hydroxyacyl, N-loweralkylaminoacyl, N,N-diloweralkylaminoacyl, hydroxy-substituted aminoacyl or an amino acid residue other than those defined above and the pharmaceutically acceptable salts thereof useful in the treatment of infections.

公开(公告)号：DE2421488A1

公开(公告)日：1974-11-21

申请号：DE2421488

申请日：1974-05-03

Applicant: ABBOTT LAB

Inventor： HALLAS ROBERT ,  MARTIN JERRY ROY ,  TADANIER JOHN SOLOMAN

IPC: A61K31/335 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/7048 ,  A61P31/04 ,  C07H17/08 ,  C07D21/00

Abstract: 1467296 Erythromycin derivatives ABBOTT LABORATORIES 1 May 1974 [4 May 1973] 19163/74 Heading C2C Novel erythromycin derivatives of the general formula wherein R is a C 1-6 alkyl, C 2-6 alkenyl, or optionally nuclear substituted aryl, benzyl or aroxyalkyl group, R 1 is a hydrogen atom or methyl group, R 2 is a hydrogen atom or C 1-6 alkanoyl group and R 3 is a hydrogen atom or hydroxyl group, provided that R 1 and R 3 are not simultaneously a hydrogen atom and the nuclear substituent is nitro, alkyl or halogen are prepared by reacting the corresponding compound in which the -OSO 2 R group is replaced by -OH with RSO 2 Cl (when R is vinyl in the product, R may be 2-bromoethyl in the starting material), followed optionally by hydrolysis or alcoholysis when R 2 is a C 1-6 alkanoyl group to give the corresponding product wherein R 2 is a hydrogen atom. Pharmaceutical compositions having antibiotic activity comprise, as active ingredient, an erythromycin derivative of the above general formula, together with an appropriate carrier.